<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549496</url>
  </required_header>
  <id_info>
    <org_study_id>OHRI-BCP-CCB-2012</org_study_id>
    <nct_id>NCT01549496</nct_id>
  </id_info>
  <brief_title>A Drug Interaction Study of Boceprevir in Combination With Amlodipine or Diltiazem in Healthy Volunteers</brief_title>
  <official_title>A Drug Interaction Study Investigating the Effect of Boceprevir on the Pharmacokinetics of the Calcium Channel Blockers Amlodipine and Diltiazem and Vice Versa in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Hospital Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ottawa Hospital Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic interactions between the
      hepatitis C NS3 protease inhibitor boceprevir and the calcium channel blockers amlodipine and
      diltiazem in healthy volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Investigator left this hospital
  </why_stopped>
  <start_date>May 2012</start_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pharmacokinetics</measure>
    <time_frame>7 days</time_frame>
    <description>AUC, Cmax, Cmin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of participants with adverse events</measure>
    <time_frame>29 days</time_frame>
    <description>description and frequency of adverse events for all participants during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>boceprevir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>boceprevir 800 mg tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>amlodipine 2.5 mg QD</description>
    <arm_group_label>boceprevir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diltiazem</intervention_name>
    <description>diltiazem 120 mg qd</description>
    <arm_group_label>boceprevir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Able and willing to sign informed consent prior to any study-related activities.

          2. Male or female subjects between 18 and 65 years of age inclusive.

          3. Healthy, i.e. not suffering from a relevant acute or chronic illness.

          4. Body Mass Index (BMI) of 17.5 to 31 kg/m2; and a total body weight &gt; 50 kg (110 lbs).

          5. Acceptable medical history, physical examination, and 12-lead ECG at screening.

          6. Acceptable laboratory values that indicate adequate baseline organ function at
             screening visit.

          7. Willing to stop using any herbal or natural health products for 2 weeks prior to and
             during the study including: Grapefruit, grapefruit juice, St. John's Wort.

          8. Willingness to abstain from alcohol use for 3 days prior to and during the study.

          9. Female subject is either not of childbearing potential, defined as postmenopausal for
             at least 1 year or surgically sterile (bilateral tubal ligation, bilateral
             oophorectomy or hysterectomy), or is of childbearing potential and practicing one of
             the following methods of birth control:

               -  Condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD)

               -  A vasectomized partner

               -  Total abstinence from sexual intercourse

        Exclusion Criteria:

          1. Have serological evidence of exposure to HIV or HCV.

          2. Known allergies to any of the study medications.

          3. Female subjects of childbearing potential who:

               -  Has a positive urine pregnancy test at screening.

               -  Is not willing to use a reliable method of barrier contraception during the
                  study.

               -  Using only oral contraceptive as a birth control method.

               -  Is breastfeeding.

          4. Inability to adhere to protocol.

          5. Use of any medications (2 weeks prior to or during the study) other than occasional
             use of acetaminophen.

          6. Female subjects using contraceptives that contain drospirenone.

          7. Subjects that are currently smoking.

          8. Subjects with hypertension or heart disease requiring medical treatment.

          9. Any condition possibly affecting drug absorption (e.g., gastro intestinal disorder).

         10. Patients may be excluded from the study for other reasons, at the investigator's
             discretion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles la Porte, PharmD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Hospital Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Investigation Unit, Ottawa Hospital Research Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>boceprevir</keyword>
  <keyword>hypertension</keyword>
  <keyword>amlodipine</keyword>
  <keyword>diltiazem</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
    <mesh_term>Calcium Channel Blockers</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

